Skip to main content
Clinical Trials/DRKS00015225
DRKS00015225
Completed
未知

utritional Status and dietary Effects on Phosphorous metabolism and clinical Symptoms in Hypophosphatasia

Klinische StudieneinheitOrthopädische Klinik König-Ludwig-HausLehrstuhl der Universität Würzburg0 sites77 target enrollmentAugust 14, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
E83.3
Sponsor
Klinische StudieneinheitOrthopädische Klinik König-Ludwig-HausLehrstuhl der Universität Würzburg
Enrollment
77
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 14, 2018
End Date
April 22, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Klinische StudieneinheitOrthopädische Klinik König-Ludwig-HausLehrstuhl der Universität Würzburg

Eligibility Criteria

Inclusion Criteria

  • Section I,II:
  • \- Adult males and females (age \>18 years)
  • \- Established diagnosis of Hypophosphatasia
  • \- Reduced Serum/Plasma ALP\-Activity below age and sex specific reference range of the respective test kit applied (measured at least twice with a minimum 4 week interval)
  • \- At least one of the items below
  • \>Genetically confirmed ALPL\-Mutation
  • \>Elevated PLP (urine or serum), above ULN
  • \>Symptoms of the disease
  • \- Signed informed consent
  • Section I (control group):

Exclusion Criteria

  • Section I,II:
  • \- Severe chronic diseases
  • \>Renal insufficiency, CKD 4 \+ 5 (eGFR\<30ml/min/KO)
  • \>Current or past history of solid or haematological neoplasia; patients are eligible when clinically stable (as judged by the investigator) and diagnosis of this neoplasia dates back \> 5 years.
  • \- Inflammatory bowel disease, or history of colostomy or small or large intestine bowel surgery where resection was performed
  • \- Coagulopathy
  • \- Intake of phosphate binders or Dialysis
  • \- Ongoing treatment with glucocorticoids \>7,5mg/d prednisolone\-equivalent
  • \- Current/previous treatment with Asfotase alfa (ERT) (section I), Current/recent treatment with Asfotase alfa (ERT) within the last 3 months before enrollment
  • \- Regular use of laxatives

Outcomes

Primary Outcomes

Not specified

Similar Trials